Canaccord Genuity Maintains Buy on Enovis, Lowers Price Target to $45

Benzinga Newsdesk www.benzinga.com Neutral 48.8%

Neg 0% Neu 48.8% Pos 0%

Canaccord Genuity analyst Caitlin Cronin maintains Enovis (NYSE:ENOV) with a Buy and lowers the price target from $50 to $45.